We here describe for the first time that PBMCs from patients with cSLE, SLE, pSjD and SSc and high type I IFN activity respond to amlexanox with downregulation of the IFN-stimulated gene MX1. The gene discussed is MX1; the disease is systemic lupus erythematosus.